{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T17:50:46Z","timestamp":1791827446939,"version":"4.3.4"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ir J Med Sci"],"DOI":"10.1007\/s11845-026-04653-z","type":"journal-article","created":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T17:25:59Z","timestamp":1791825959000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effects of tyrosine kinase inhibitors in treatment of non small cell lung cancer patients with brain metastases, real world experience"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8354-7922","authenticated-orcid":false,"given":"Mehmet Akif","family":"T\u00fckenmez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gamze","family":"Emin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00fcleyman","family":"Karake\u00e7i","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esra","family":"A\u015f\u0131k","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeynep","family":"Sa\u011fnak Y\u0131lmaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evren","family":"Kara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,12]]},"reference":[{"issue":"7","key":"4653_CR1","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1002\/ijc.35278","volume":"156","author":"AM Filho","year":"2025","unstructured":"Filho AM, Laversanne M, Ferlay J et al (2025) The GLOBOCAN 2022 cancer estimates: Data sources, methods, and a snapshot of the cancer burden worldwide. Int J Cancer 156(7):1336\u20131346","journal-title":"Int J Cancer"},{"issue":"2","key":"4653_CR2","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3322\/caac.20107","volume":"61","author":"A Jemal","year":"2011","unstructured":"Jemal A, Bray F, Center MM et al (2011) Mar-Apr) Forman D. Global cancer statistics. CA Cancer J Clin 61(2):69\u201390. https:\/\/doi.org\/10.3322\/caac.20107","journal-title":"CA Cancer J Clin"},{"key":"4653_CR3","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.ejca.2021.12.005","volume":"162","author":"A Steindl","year":"2022","unstructured":"Steindl A, Brunner TJ, Heimbach K et al (2022) Feb) Changing characteristics, treatment approaches and survival of patients with brain metastasis: data from six thousand and thirty-one individuals over an observation period of 30 years. Eur J Cancer 162:170\u2013181","journal-title":"Eur J Cancer"},{"issue":"5","key":"4653_CR4","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/s41571-019-0320-3","volume":"17","author":"JH Suh","year":"2020","unstructured":"Suh JH, Kotecha R, Chao ST et al (2020) Current approaches to the management of brain metastases. Nat Rev Clin Oncol 17(5):279\u2013299","journal-title":"Nat Rev Clin Oncol"},{"key":"4653_CR5","doi-asserted-by":"publisher","first-page":"100987","DOI":"10.1016\/j.drup.2023.100987","volume":"70","author":"WJ Liu","year":"2023","unstructured":"Liu WJ, Wang L, Zhou FM et al (2023) Elevated NOX4 promotes tumorigenesis and acquired EGFR-TKIs resistance via enhancing IL-8\/PD-L1 signaling in NSCLC. Drug Resist Updat 70:100987","journal-title":"Drug Resist Updat"},{"issue":"8","key":"4653_CR6","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/S1470-2045(11)70184-X","volume":"12","author":"C Zhou","year":"2011","unstructured":"Zhou C, Wu YL, Chen G et al (2011) Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 12(8):735\u2013742","journal-title":"Lancet Oncol"},{"issue":"9","key":"4653_CR7","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1093\/annonc\/mdv270","volume":"26","author":"YL Wu","year":"2015","unstructured":"Wu YL, Zhou C, Liam CK et al (2015) Sep) First-line erlotinib versus gemcitabine\/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study. Ann Oncol 26(9):1883\u20131889","journal-title":"Ann Oncol"},{"issue":"1","key":"4653_CR8","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJMoa1913662","volume":"382","author":"SS Ramalingam","year":"2020","unstructured":"Ramalingam SS, Vansteenkiste J, Planchard D et al (2020) FLAURA Investigators. Overall Survival with Osimertinib in Untreated, EGFRMutated Advanced NSCLC. N Engl J Med 382(1):41\u201350","journal-title":"N Engl J Med"},{"issue":"8","key":"4653_CR9","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1016\/j.annonc.2020.04.478","volume":"31","author":"T Mok","year":"2020","unstructured":"Mok T, Camidge DR, Gadgeel SM et al (2020) Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study. Ann Oncol 31(8):1056\u20131064","journal-title":"Ann Oncol"},{"issue":"4","key":"4653_CR10","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/S2213-2600(22)00437-4","volume":"11","author":"BJ Solomon","year":"2023","unstructured":"Solomon BJ, Bauer TM, Mok TSK et al (2023) Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALKpositive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study. Lancet Respir Med 11(4):354\u2013366","journal-title":"Lancet Respir Med"},{"issue":"5 Suppl","key":"4653_CR11","doi-asserted-by":"publisher","first-page":"e455S","DOI":"10.1378\/chest.12-2366","volume":"143","author":"MJ Simoff","year":"2013","unstructured":"Simoff MJ, Lally B, Slade MG et al (2013) Symptom management in patients with lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 143(5 Suppl):e455S\u2013e497S","journal-title":"Chest"},{"issue":"9","key":"4653_CR12","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1002\/cncr.21818","volume":"106","author":"C Hu","year":"2006","unstructured":"Hu C, Chang EL, Hassenbusch SJ 3 et al (2006) Nonsmall cell lung cancer presenting with synchronous solitary brain metastasis. Cancer 106(9):1998\u20132004","journal-title":"Cancer"},{"issue":"1","key":"4653_CR13","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.lungcan.2015.01.020","volume":"88","author":"D Rangachari","year":"2015","unstructured":"Rangachari D, Yamaguchi N, VanderLaan PA et al (2015) Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers. Lung Cancer 88(1):108\u2013111","journal-title":"Lung Cancer"},{"issue":"11","key":"4653_CR14","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1016\/S1470-2045(23)00444-8","volume":"24","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Vaccarella S, Morgan E, Li M et al (2023) Global variations in lung cancer incidence by histological subtype in 2020: a population-based study. Lancet Oncol 24(11):1206\u20131218","journal-title":"Lancet Oncol"},{"issue":"1","key":"4653_CR15","doi-asserted-by":"publisher","first-page":"124","DOI":"10.3122\/jabfm.2015.01.140072","volume":"28","author":"C Rolfo","year":"2015","unstructured":"Rolfo C, Passiglia F, Ostrowski M et al (2015 Jan-Feb) Improvement in lung cancer outcomes with targeted therapies: an update for family physicians. J Am Board Fam Med 28(1):124\u2013133","journal-title":"J Am Board Fam Med"},{"issue":"4","key":"4653_CR16","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/S2213-2600(22)00437-4","volume":"11","author":"BJ Solomon","year":"2023","unstructured":"Solomon BJ, Bauer TM, Mok TSK et al (2023) Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALKpositive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study. Lancet Respir Med 11(4):354\u2013366","journal-title":"Lancet Respir Med"},{"issue":"8","key":"4653_CR17","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.3390\/cancers15082382","volume":"15","author":"V Tatineni","year":"2023","unstructured":"Tatineni V, O\u2019Shea PJ, Ozair A et al (2023) First- versus Third-Generation EGFR Tyrosine Kinase Inhibitors in EGFR-Mutated Non-Small Cell Lung Cancer Patients with Brain Metastases. Cancers (Basel) 15(8):2382","journal-title":"Cancers (Basel)"},{"issue":"6","key":"4653_CR18","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1093\/annonc\/mdy121","volume":"29","author":"S Novello","year":"2018","unstructured":"Novello S, Mazi\u00e8res J, Oh IJ, de Castro J et al (2018) Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)- positive non-small-cell lung cancer: results from the phase III ALUR study. Ann Oncol 29(6):1409\u20131416","journal-title":"Ann Oncol"},{"issue":"34","key":"4653_CR19","doi-asserted-by":"publisher","first-page":"e27038","DOI":"10.1097\/MD.0000000000027038","volume":"100","author":"B Lan","year":"2021","unstructured":"Lan B, Wang Y, Wu J et al (2021) The predictive and prognostic effects of PD-L1 expression on TKI treatment and survival of EGFR-mutant NSCLC: A metaanalysis. Med (Baltim) 100(34):e27038","journal-title":"Med (Baltim)"},{"issue":"10183","key":"4653_CR20","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","volume":"393","author":"TSK Mok","year":"2019","unstructured":"Mok TSK, Wu YL, Kudaba I et al (2019) KEYNOTE042 Investigators. Pembrolizumab versus chemotherapy for previously untreated, PDL1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE042): a randomised, open-label, controlled, phase 3 trial. Lancet 393(10183):1819\u20131830","journal-title":"Lancet"},{"issue":"2","key":"4653_CR21","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/S1470-2045(20)30641-0","volume":"22","author":"L Paz-Ares","year":"2021","unstructured":"Paz-Ares L, Ciuleanu TE, Cobo M et al (2021) First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, openlabel, phase 3 trial. Lancet Oncol 22(2):198\u2013211","journal-title":"Lancet Oncol"}],"container-title":["Irish Journal of Medical Science (1971 -)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11845-026-04653-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11845-026-04653-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11845-026-04653-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T17:26:00Z","timestamp":1791825960000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11845-026-04653-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,12]]},"references-count":21,"alternative-id":["4653"],"URL":"https:\/\/doi.org\/10.1007\/s11845-026-04653-z","relation":{},"ISSN":["0021-1265","1863-4362"],"issn-type":[{"value":"0021-1265","type":"print"},{"value":"1863-4362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,12]]},"assertion":[{"value":"22 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All procedures performed in the study involving human participants werein accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Ethical approval was received from Karadeniz Technical University Faculty of Medicine Ethics Committee with the protocol number 2023\/170 was obtained on 07.12.2023 before the start of study.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":2,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}